Urinary tract infections with extended-spectrum β-lactamases (ESBL) are an increasing public health concern. We evaluated our experience with the use of ertapenem for complicated urinary tract infections (cUTI) caused by ESBL-producing bacteria. Sixty-four patients aged >18 years who had a cUTI caused by ESBL-producing microorganisms that were treated with ertapenem at Sisli Etfal Training and Research Hospital, from January 1st, 2010 to December 31st, 2011, were included in this study. Data on patients demographic, clinical and laboratory results were collected. The median age was 65.8 years (range, 30 to 95). All patients had at least one risk factor complicating factor except two of them. The most common underlying problem was prior antibiotic exposure. The pathogens isolated from urine samples were ESBL-producing E. coli in 49, ESBL-producing K. pneumoniae in 12 and ESBL-producing K. oxytoca in 2 patients. All were susceptible to ertapenem in vitro. The average duration of ertapenem therapy was 14±4 days for upper UTI and 11±2 days for lower UTI. All patients achieved clinical cure and bacteriological eradication in urine. One patient had relapse and six of them had reinfection. Only one case had diarrhea which did not require discontinuation of therapy. Our results demonstrate that ertapenem is suitable for the treatment of cUTI caused by ESBL-producing bacteria.

Introduction

Urinary tract infection is the most common bacterial illness occurring in adults (1). Urinary tract infections (UTIs) are among the most prevalent infectious diseases in the general population, with an estimated overall incidence of 18/1000 person per year. UTIs are classified into complicated and uncomplicated regardless of the site and severity of the infection (2). The distinction between an uncomplicated UTI and a complicated UTI is important because of implications to pre- and post-treatment evaluation and the type and duration of antimicrobial regimens. Complicated UTI (cUTI) is characterized by the presence of structural abnormalities (e.g. urinary obstructions), metabolic and/or hormonal abnormalities (diabetes mellitus, pregnancy, renal impairment, etc.), and impaired host responses (transplant recipients, neutropenic patients, etc.) (3).

There are a number of sequelae from complicated UTIs that may have serious or fatal consequences (4). Therefore, patients with cUTIs require more diagnostic testing, broad-spectrum empiric antimicrobial therapy, and a longer duration of treatment (2).

Extended-spectrum β-lactamases (ESBLs) are enzymes that confer resistance to most β-lactam antibiotics. ESBL-producing bacteria also typically show increased levels of resistance to other agents and therefore treatment options are often limited. Over the past 10 years there has been an increase in incidence of infections due to ESBL-producing organisms globally (5).
A recent report from the Infectious Diseases Society of America listed ESBL-producing Klebsiella spp and E coli as one of the six drug-resistant microbes to which new therapies are urgently needed (6).

Ertapenem is a parenteral broad spectrum carbapenem that was used to once daily. It is approved for the following infections: complicated intra-abdominal infections, complicated skin and skin-structure infections, acute pelvic infections, complicated urinary tract infections and community-acquired pneumonia and for the prophylaxis of surgical-site infection following elective colorectal surgery in adult patients. It is active against many Gram-positive and negative bacteria, including several anaerobic organisms but has a narrower spectrum of antimicrobial activity, compared with older carbapenems (7). Ertapenem is active against ESBL-producing Enterobacteriaceae in vitro (8). However there are no randomized controlled trials of therapy for complicated UTI caused ESBL-producing bacteria (9). The objective of our case series was to examine the clinical and microbiologic outcomes and relapses associated with ertapenem treatment of patients with complicated UTI caused ESBL producing bacteria.

Material and Methods

Sixty-four patients aged > 18 y who had a cUTI caused by ESBL-producing microorganisms that was treated with ertapenem at the Sisli Etfal Training and Research Hospital, from 1 January 2010 to 31 December 2011, were included this study. In this retrospective study, the patients were detected through the hospital’s pharmacy records by screening the antibiotic prescriptions used.

Relevant parameters such as patient characteristics, underlying diseases, clinical manifestations, laboratory and radiological test results, and treatment modalities used before ertapenem treatment, were evaluated.

In the case of an indwelling urinary catheter, diabetes mellitus, neurogenic bladder, obstruction due to nephrolithiasis, tumour or fibrosis, urinary retention due to benign prostatic hypertrophy, bladder cancer or other urological anatomical abnormalities were considered to be complicated (10).

UTIs were confirmed by positive urine cultures and quantitative bacterial counts. If septicemia secondary to a UTI was suspected, appropriate blood samples were obtained for culture before treatment.

Urine specimens were Gram-stained, and causative pathogens isolated by culture were identified by Standard microbiological techniques in our microbiology laboratory. The isolates were tested for susceptibility to ertapenem. The susceptibility was determined by disk diffusion test on Mueller – Hinton agar according to the methodology and inhibition zone diameters recommended by the Clinical and Laboratory Standards Institute (11). ESBL was detected by modified double-disk synergy test with cefotaxime and ceftazidime disks (Becton Dickinson, Sparks, MD, USA) on opposite sides of an amoxicillin/clavulanic acid disk at 25 mm apart.

Clinical assessments, laboratory tests and cultures taken were repeated during antibiotic treatment and follow-up.

Patients received ertapenem 1g once a day (Invanz; Merck & Co., Inc.) intravenously with a 30 min infusion. If creatinine clearance was < 30 mL/min/1.73 m2, dose adjustment made 500mg once a day.

Criteria for response: Clinical success was defined as resolution of symptoms on the control visit, and microbiological success was defined as a sterile control urine culture performed 7-9 days after the last dose of the drug in accordance with the Infectious Diseases Society of America (IDSA) guidelines (12). Superinfection was defined as the isolation of one or more new pathogens from urine at shortterm follow-up (13). Relapse was defined as isolation of the pretreatment pathogen in the control urine cultures performed 28-31 days after the end of therapy. Reinfection was defined as any pathogen in the control urine cultures performed 28-31 days after the end of therapy (14).

We performed descriptive statistical methods to demonstrate demographic and basic clinical features. Statistical analysis was performed using Stata SE/12. (StataCorp LP, Texas USA).

Results

Sixty-four patients with median age of 65.8±14.4 years (range, 30 to 95) were assessed. The demographic and clinical data are shown in table 1.

The average total length of hospital stay was 22 days. (Range: 7-50 days) All patients had at least one risk factor complicating factor except two. The most common underlying problem was prior antibiotic exposure. Forty three patients had more than one complicating factor. The laboratory results of the patients are shown in table 2.

If septicemia secondary to a UTI was suspected,
appropriate blood samples were obtained for culture before treatment. Eighteen patients had positive blood cultures and the isolated microorganisms were: E.coli:13, Klebsiella pneumoniae:3, Klebsiella oxytoca:1, Enterobacter cloacae:1. The microorganisms isolated from urine samples are shown in table 3.

All pathogens were resistant to ciprofloxacin and TMP-SXT but were susceptible to ertapenem, imipenem/clastatin and meropenem. Therapy was switched to ertapenem in thirty six patients after obtaining the urine culture results. Among these patients 24 of them previously received beta lactam-beta lactamase combination, 4 other carbapenems, 8 ceftriaxone. Thirteen patients had glomerular filtration rate (GFR) < 30 ml/min and all of them received ertapenem as 500 mg daily. Eleven patients were on haemodialysis. The average duration of ertapenem therapy was 14±24 days for upper UTI and 11±2 days for lower UTI. All patients achieved clinical cure and bacteriological eradication in urine.

Two patients developed secondary infection. One patient had malignancy involving the urinary tract, nephrostomy tube and previously received imipenem. This patient had upper urinary tract infection caused by Acinetobacter baumanii which developed on the tenth day of ertapenem therapy. The other patient had upper urinary tract infection caused by Enterococcus spp. These two patients had treatment modifications. Relapse appeared in only one patient. This patient had risk factors as older age, prostatic hypertrophy and long-term indwelling catheter. Six patients had reinfection and two of them developed colonization after stopping the treatment. Only one case had diarrhea which did not require discontinuation of therapy.

Discussion

ESBL- producing Enterobacteriaceae have been reported worldwide, most often in hospital specimens but also in samples from the community (15). Risk factors identified as predictors of ESBL with organisms are prolonged length of hospitalization, underlying disease, urinary catheters, prior exposure to antibiotics, surgical procedures and immunosuppressive therapy (16-18). Treatment options for patients with infection caused by ESBL-producing Enterobacteriaceae are limited (19). Inadequate ampicic antibiotherapy may cause treatment failure and increase the mortality risk (20). A parenteral carbapenem is often the only suitable antimicrobial agent (18). Frequent use of carbapenem will probably ensue which may in turn have untoward consequences.

| Table 1. Demographic and clinical data of the patients. |
|--------------------------------------------------------|
| Characteristic                                         | Number of patients (%) |
| Mean age (range) years                                 | 65.8 (30-95)           |
| Male                                                   | 41 (64)                |
| Prior hospitalization within last 3 months             | 34 (53)                |
| Long-term indwelling catheter                          | 23 (35)                |
| Clean intermittent catheterization                     | 4 (6)                  |
| Prior antibiotic exposure                              | 52 (81)                |
| Diabetes mellitus                                     | 15 (23)                |
| Cardiac disease                                        | 5 (8)                  |
| Malignancy involving the urinary tract                 | 14 (22)                |
| Pulmonary disease                                      | 4 (6)                  |
| Nephrolithiasan                                        | 13 (20)                |
| Benign prostatic hypertrophy                           | 15 (23)                |
| Nephrostomy tube                                       | 3 (5)                  |
| Prostate biopsy                                        | 4 (6)                  |
| Chronic renal failure                                  | 13 (20)                |

| Table 2. Laboratory results of the patients. |
|---------------------------------------------|
| n WBC/mm3 Neutrophil (%) CRP (folds) |
| Lower UTI 13 | 6400±1600 | 63±20 | 523 |
| Upper UTI 51 | 16,200±8500 | 84±10 | 23±13 |

| Table 3. The microorganisms isolated from urine samples. |
|----------------------------------------------------------|
| E.coli K. pneumoniae K. oxytoca Culture negative samples |
| Lower UTI 9 4 0 0 |
| Upper UTI 40 8 2 1 |
| Total 49 12 2 1 |
on the prevalence of resistance to these antibiotics in microorganisms (21).

Ertapenem is a broad-spectrum carbapenem and ideal choice for outpatient parenteral antibiotic therapy (OPAT) because of its once daily parenteral dosage. It has been shown to have good in vitro activity against ESBL producing bacteria (22). There are few observational studies with ertapenem for the treatment of infections caused by ESBL producing organisms. Firstly, Teng at al in 2007 showed excellent efficacy of ertapenem for the treatment of ESBL producing gram negative bacterial infections, comparable with either imipenem or meropenem (23). Melody Berg at al in 2008 showed successful clinical and microbiological results with ertapenem consolidation therapy (19).

Recent studies suggest that the treatment of ESBL-producing E. coli or Klebsiella bacteriemias with ertapenem was as effective as imipenem or meropenem when compared with the terms of mortality and microbiological response (24).

ESBL production by Enterobactericeae family is increasing in studies reported from Turkey. Infections caused by ESBL producing microorganisms are a serious problem in a Teaching and Research hospital with 800 beds like ours. In a study conducted at our hospital in 2009 it was found that 19.7% of Klebsiella spp and 11.5% of E.coli produce ESBL (25). In a previous study from our hospital it was reported that treatment of UTI caused by ESBL producing bacteria with ertapenem had favorable clinical response (26).

In our study, ertapenem was well tolerated and all patients achieved clinical cure, one patient had relapse and six of them had reinfection.

Previous studies have illustrated that prior use of imipenem or meropenem is associated with colonization or infection due to multidrug resistant A. baumannii, P. aeruginosa (27). Ertapenem has limited activity against A. baumannii and P. aeruginosa. It is still controversial whether the usage of ertapenem has an impact on the susceptibility patterns of P.aeruginosa to other carbapenems. Reports of the development of carbapenem resistance during carapenem therapy, including ertapenem, are concerning (28). In our study resistance to ertapenem was not observed to have developed during therapy.

In conclusion, ertapenem is suitable the treatment of ESBL producing cUTI. (Because of effective, lower cost, feasibility in outpatient parenteral antibiotic therapy and potential benefit in reducing carbapenem resistance in A. baumanii and P. aeruginosa). Further prospective randomised controlled studies are needed.

**Declaration of Interest:** We state that there is no conflict of interest.

**Funding:** None.

**References**

1. Nicolle LE. Update in adult urinary tract infection. Curr Infect Dis Rep. 2011;13:552-60.
2. Bader MS, Hawboldt J, Brooks A. Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med. 2010;122:7-15.
3. Hsueh PR, Hoban DJ, Carmeli Y, Chen SY, Desikan S, Alejandria M, et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect. 2011;63:114-23.
4. Neal DE, Jr. Complicated urinary tract infections. Urol Clin North Am. 2008;35:13-22.
5. Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J Antimicrob Chemother. 2010;65:1510-3.
6. Pitout JD, Lapland KB. Extended-spectrum beta-lactamae-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159-66.
7. Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother. 2007;8:237-56.
8. Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M, et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis. 2012;74:62-7.
9. Wu Ul, Chen WC, Yang CS, Wang JL, Hu FC, Chang SC, et al. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis. Int J Infect Dis. 2012;16:47-52.
10. Pulukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents. 2007;29:62-5.
11. Ferraro MJ, Wikler MA, Clinical and Laboratory Standarts Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved
11. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992;15:216-27.

12. Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother. 2004;53:67-74.

13. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents. 2012;40:554-6.

14. Munoz-Price LS, Jacoby GA. Extended spectrum beta-lactamases. Wolters Kluwer Health; [updated 2014 Mar; cited 2014 Apr]. Available from: http://www.uptodate.com

15. Kang CI, Wi YM, Lee MY, Ko KS, Chung DR, Peck KR, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012;50:312-7.

16. Rodríguez-Baño J, Picón E, Gijón P, Hernández JR, Ruíz M, Peña C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010;50:40-8.

17. Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70:313-33.

18. Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. Ann Pharmacother. 2008;42:207-12.

19. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31-7.

20. Martínez JA, Aguilar J, Almela M, Mohapatra S, Casellas JM, Goossens H, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteremia. The Journal of antimicrobial chemotherapy. 2006;58:1082-5.

21. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents Chemother. 1997;41:1830-1.

22. Teng CP, Chen HH, Chan J, Lyé DCB. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections. Int J Antimicrob Agents. 2007;30:356-9.

23. Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC. Carbapenem therapy for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis. 2011;70:150-3.

24. Bayraktar B, Toksoy B, Bulut E. [Detection of bla(CTX-M) beta-lactamase genes in extended-spectrum beta-lactamase producing gram-negative bacteria]. Mikrobiyol Bul. 2010;44:187-96.

25. Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect. 2006;64:7-15.

26. Skurnik D, Lasocki S, Bremont S, Muller-Serleys C, Kitzis MD, Courvalin P, et al. Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. J Med Microbiol. 2010;59:115-9.